14 results about "Meningococcal carriage" patented technology

The present invention provides fusion proteins having the desire to reduce Factor H binding, in particular the present invention provides optimized processes for the manufacture of fusion proteins and formulations comprising fusion proteins. The present invention provides an effective platform process for the manufacture of an effective vaccine formulation against Neisseria meningitidis, which meets a variety of criteria, including improved immunogenicity, safety, stability, and burdenability.

The present application provides a kind of protecting group B meningococcal infection outer membrane vesicle composition, the outer membrane vesicle composition is by lipopolysaccharide modified group B meningococcal outer membrane vesicle and the outer membrane vesicle of group B meningococcal bacterium expressing recombinant protein is composed.The outer membrane vesicle composition provided by the present application has better protective effect on group B meningococcal infection relative to single strain outer membrane vesicle, and is more suitable for use as vaccine.

The present invention provides a fusion protein in which H factor binding is desiredly reduced, and in particular, the present invention provides an optimized manufacturing process for the fusion protein and formulations containing the fusion protein. The present invention provides an efficient platform process for producing effective vaccine formulations against Neisseria meningitidis that meet multiple criteria with improved immunogenicity, safety, stability and availability.

This application relates to the technical field of biomedicine, and particularly to a meningococcal outer membrane protein synthetic peptide and its application. This application discloses a meningococcal outer membrane protein synthetic peptide and its application. The amino acid sequence of the polypeptide is at least one of (I) to (IV): (I) the amino acid sequence shown in SEQ ID NO.1; (II) the amino acid sequence shown in SEQ ID NO.2; (III) the amino acid sequence shown in SEQ ID NO.3; (IV) the amino acid sequence shown in SEQ ID NO.4. This application discloses a meningococcal outer membrane protein synthetic peptide and its application, and discloses the polypeptide sequence. The vaccine made from this polypeptide or its polymer can effectively cope with the antigen diversity of meningococcal PorA and PorB, is easy to synthesize on a large scale, and has good application prospects.

A method of treating a patient with a complement-associated disorder with a complement inhibitor and then monitoring the patient during administration of the complement inhibitor and thereafter. The method includes certifying a prescriber and a dispenser and then monitoring the patient during and after administration of the complement inhibitor for an adverse event, including a meningococcal or pneumococcal event.

The invention discloses a group B meningococcus vaccine composition as well as a preparation method and application thereof. The vaccine composition comprises a factor H binding protein (fHbp) fusion protein and an outer membrane vesicle (OMV) wherein the factor H binding protein fusion protein comprises a meningococcal heparin binding protein antigen (NHBA) or a variant thereof, and an operably linked fHbp or a variant thereof. The vaccine composition can induce an organism to generate a functional antibody with bactericidal activity, has bactericidal activity on three variant strains, can induce the organism to generate higher protective response, and improves the bactericidal coverage rate of the vaccine on domestic B group strains.

The invention provides a method for purifying group C meningococcus capsular polysaccharide. The method comprises a rough preparation step and a refining step, wherein in the refining step, two-step elution purification or flow-through combined elution purification is adopted for refining. The refined capsular polysaccharide prepared by the invention meets part of quality standards required by pharmacopeia, and does not use organic solvents and toxic reagents, such as ethanol, phenol, acetone, cetyltrimethylammonium bromide (CTAB) and the like, so that the harm of the capsular polysaccharide to human bodies and the environment is avoided. The method provided by the invention also has the advantages of simple process steps, short process time consumption, reduced production cost, high safety and the like.

The present invention relates to the technical field of MenB vaccines, and specifically to a self-replicating mRNA sequence, a vaccine for preventing MenB, and a method for preparing the same. A self-replicating mRNA sequence comprises RNA encoding a region in an amino acid sequence, wherein the amino acid sequence comprises a single sequence shown in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, which is concatenated in any order to form a tandem sequence. The present application screens amino acid sequences for strains found in China's monitoring coverage, provides a vaccine for preventing MenB, and reduces the mortality rate caused by meningococcal B infection in China. The vaccine for preventing MenB provided by the present application has a low number of injection needles, a low dose, and a high expression effect, which can reduce the dosage and frequency of administration, while improving the expression efficiency of the vaccine, in order to achieve a better immune effect.

This application relates to the technical field of vaccine conjugates, specifically to a method for preparing a polysaccharide conjugate of group A meningococcal capsular polysaccharide, including the preparation of polysaccharide derivatives, mixing ratio, conjugation reaction, aging treatment, ultrafiltration and sterilization steps. This application eliminates the pH adjustment and conjugate purification steps in the activation process by optimizing the process parameters, but the quality of the harvested polysaccharide conjugate still meets the national standards, thereby simplifying the preparation process of polysaccharide conjugates and shortening the preparation cycle of polysaccharide conjugates.

The invention relates to the technical field of MenB vaccines, in particular to a self-replicating mRNA sequence, a MenB prevention vaccine and a preparation method of the self-replicating mRNA sequence and the MenB prevention vaccine. The self-replicating mRNA sequence comprises RNA of a coding region in an amino acid sequence, and the amino acid sequence comprises a tandem sequence formed by tandem connection of single sequences shown as SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10 according to any sequence. Amino acid sequences are screened for strains with coverage found in Chinese monitoring, the vaccine for preventing MenB is provided, and the death rate caused by domestic infection due to B-type meningococcus is reduced. The vaccine for preventing MenB has the advantages of being low in injection needle number, low in dosage and high in expression effect, the dosage and frequency can be reduced, meanwhile, the expression efficiency of the vaccine is improved, and the vaccine for preventing MenB is suitable for clinical application. And a better immune effect is expected to be achieved.

The invention belongs to the field of gene engineering, and particularly discloses a soluble recombinant diphtheria toxin mutant CRM197 protein and a preparation method thereof, and the specific steps are as follows: a codon-optimized diphtheria toxin mutant CRM197 coding sequence is connected to an expression vector pBAD-HisB, and inducible expression is performed in Escherichia coli BW25113; the diphtheria toxin mutant CRM197 is converted into soluble expression from inclusion body by adding a signal peptide sequence at the N terminal, and after fermentation optimization and multi-step purification, the protein purity reaches 95% or above, and the yield is 600 mg / L or above; the invention also provides a fusion protein containing the soluble recombinant diphtheria toxin mutant CRM197 and a group B meningococcus fHBP-V1 or fHBP-V2 fragment, and the fusion protein can be used for developing a group B meningococcus vaccine.

The present invention relates to combination vaccine comprising hexavalent serogroup of Neisseria meningitidis for prevention and prophylaxis of infection caused by meningococcal bacteria. The present invention relates to a hexavalent combination vaccine comprising serogroups A, B, C, Y, W, X of Neisseria meningitidis. The present invention relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroups A, C, Y, W, X and proteins of serogroup B of Neisseria meningitidis. The present invention specifically relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroup A, C, Y, W, X and mutated Factor H binding proteins (fHbp) of serogroup B of Neisseria meningitidis. The present invention further relates to the composition, use and process of preparation of hexavalent combination vaccine.